<DOC>
	<DOC>NCT02898116</DOC>
	<brief_summary>This is an open-label, multicenter, single-arm study to evaluate the safety and preliminary efficacy of a targeted therapy for NSCLC in combination with a checkpoint inhibitor: - Ensartinib (X-396), an anaplastic lymphoma kinase (ALK) Inhibitor and - Durvalumab (MEDI4736), an anti-programmed cell death ligand 1 (PD-L1) antibody.</brief_summary>
	<brief_title>A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologic confirmation of metastatic nonsmall cell lung cancer (NSCLC) and confirmed ALK rearrangement. Measurable disease according to RECIST 1.1. Availability of archival (diagnostic) specimens and willing to undergo a pretreatment biopsy. Subjects with treated brain metastases must have been treated with surgery and/or radiation therapy â‰¥ 21 days prestudy and must be clinically stable. Laboratory parameters for vital functions should be in the normal range or not clinically significant. Body weight &gt; 30 kilograms. Treatment with an investigational agent within 4 weeks of starting treatment. Prior treatment with antiPD1, PDL1, or CTLA4, or ensartinib (X396). Active, suspected or prior documented autoimmune disease. Subjects with clinically significant cardiovascular disease. History of pneumonitis or interstitial lung disease, or any unresolved immunerelated adverse events. Major surgery within 4 weeks of starting treatment. Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus. History of allogenic organ transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALK-rearranged</keyword>
	<keyword>ALK-positive</keyword>
	<keyword>ALK Inhibitor</keyword>
	<keyword>Ensartinib</keyword>
	<keyword>X-396</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>ALK</keyword>
</DOC>